Next Steps for LOXO-292 in RET-Mutant Medullary Thyroid Cancer

Alexander E. Drilon, MD, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers and <em>RET</em>-mutant medullary thyroid cancers.

Alexander E. Drilon, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps for LOXO-292 in 2 subsets of patients: those with RET fusion-positive cancers andRET-mutant medullary thyroid cancers (MTC).